Name: Voglistar GM1 Tablet ER
Brand: Mankind Pharma Ltd
SKU: 38667
Availability: InStock

Voglistar GM1 Tablet ER is an advanced oral antidiabetic medication specifically developed for managing type 2 diabetes mellitus in adults. This extended-release formula brings together three powerful active ingredients—Glimepiride, Metformin, and Voglibose—each targeting a different aspect of blood sugar regulation. The result is a synergistic approach that helps maintain steady glucose levels throughout the day, particularly after meals when spikes tend to occur.

Glimepiride, a sulfonylurea, stimulates the pancreas to release more insulin, thereby helping the body to efficiently lower circulating blood sugar. Metformin, belonging to the biguanide class, reduces glucose production in the liver, slows down sugar absorption in the intestines, and improves insulin sensitivity across body tissues. Voglibose, an alpha-glucosidase inhibitor, works by delaying the digestion and absorption of carbohydrates in the small intestine, effectively controlling postprandial blood sugar spikes. Together, these three agents offer comprehensive glycemic control for individuals whose diabetes is not well-managed with single or dual therapy.

This tablet should be taken with or just before food, as advised by your healthcare provider. It’s important to follow a consistent daily schedule when taking Voglistar GM1 Tablet ER to get the maximum benefit from the treatment. Skipping doses or discontinuing use without medical advice can lead to uncontrolled blood sugar levels, increasing the risk of long-term complications such as nerve damage, kidney dysfunction, vision loss, and cardiovascular disease.

Patients taking this medication may experience mild side effects, particularly during the early stages of treatment. Common side effects include nausea, abdominal discomfort, diarrhea, loss of appetite, and occasional low blood sugar episodes (hypoglycemia). Symptoms of hypoglycemia can include sweating, dizziness, headache, and trembling. To manage this, patients are advised to maintain regular meals and carry a quick source of glucose like fruit juice or glucose tablets at all times. Some individuals may also experience altered taste, swelling, blurred vision, or upper respiratory infections.

Voglistar GM1 Tablet ER is not recommended for individuals with type 1 diabetes, severe liver or kidney impairment, or diabetic ketoacidosis. It is also important to avoid alcohol while using this medication, as it may increase the risk of low blood sugar. Patients with pre-existing heart conditions or those who are pregnant or breastfeeding should consult their doctor before starting this treatment. Regular monitoring of blood glucose, kidney function, and liver enzymes is advised during the course of therapy to ensure safety and effectiveness.

If a dose is missed, it should be taken as soon as remembered unless it’s close to the time for the next scheduled dose. In that case, skip the missed dose—do not double up to compensate.

By combining multiple mechanisms of action into a single extended-release tablet, Voglistar GM1 offers a convenient and effective solution for long-term diabetes management. When paired with a healthy lifestyle, regular exercise, and dietary discipline, it plays a critical role in helping patients maintain better control over their condition and reduce the risk of diabetes-related complications.

Product Variants & Keywords: Voglistar GM1 Tablet ER, Voglistar GM Tablet, Voglistar GM1 ER Tablet, Glimepiride Metformin Voglibose Tablet, diabetes combination medicine, triple-action antidiabetic tablet, extended-release sugar control tablet, type 2 diabetes oral medication India, blood glucose control medicine